Shares of Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $21.72 and traded as high as $30.85. Pro-Dex shares last traded at $30.50, with a volume of 8,020 shares changing hands.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on PDEX shares. StockNews.com raised Pro-Dex from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 7th. Ascendiant Capital Markets lifted their price target on shares of Pro-Dex from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Monday, September 9th.
Read Our Latest Analysis on Pro-Dex
Pro-Dex Trading Up 1.7 %
The firm has a fifty day moving average of $26.78 and a 200-day moving average of $21.72. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.66 and a current ratio of 2.84. The stock has a market capitalization of $102.99 million, a price-to-earnings ratio of 49.19 and a beta of 0.39.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its earnings results on Thursday, September 5th. The medical instruments supplier reported $0.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.35 by $0.11. The business had revenue of $15.03 million during the quarter. Pro-Dex had a return on equity of 6.82% and a net margin of 3.95%. As a group, equities analysts predict that Pro-Dex, Inc. will post 1.42 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in PDEX. Renaissance Technologies LLC lifted its holdings in Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock worth $240,000 after buying an additional 900 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Pro-Dex by 5.1% during the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier's stock worth $1,238,000 after acquiring an additional 3,067 shares during the last quarter. Finally, Perritt Capital Management Inc. lifted its stake in shares of Pro-Dex by 43.3% in the first quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier's stock worth $106,000 after acquiring an additional 1,813 shares in the last quarter. 15.28% of the stock is currently owned by hedge funds and other institutional investors.
About Pro-Dex
(
Get Free Report)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Further Reading
Before you consider Pro-Dex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.
While Pro-Dex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
